(S (NP (NP (DT The) (NN study)) (PP (IN of) (NP (NP (NML (JJ high) (HYPH -) (NN throughput)) (JJ genomic) (NNS profiles)) (PP (IN from) (NP (DT a) (NNS pharmacogenomics) (NN viewpoint)))))) (VP (VBZ has) (VP (VBN provided) (NP (JJ unprecedented) (NNS insights)) (PP (IN into) (NP (NP (DT the) (JJ oncogenic) (NNS features)) (VP (VBG modulating) (NP (NN drug) (NN response))))))) (. .))
(S (NP (NP (DT A) (JJ recent) (NN screening)) (PP (IN of) (NP (NP (QP (SYM ~) (CD 1,000)) (NML (NN cancer) (NN cell)) (NNS lines)) (PP (IN to) (NP (NP (DT a) (NN collection)) (PP (IN of) (NP (JJ anti-cancer) (NNS drugs)))))))) (VP (VBD illuminated) (NP (NP (DT the) (NN link)) (PP (IN between) (NP (NNS genotypes) (CC and) (NN vulnerability))))) (. .))
(S (ADVP (RB However)) (, ,) (PP (IN due) (PP (IN to) (NP (NP (JJ essential) (NNS differences)) (PP (IN between) (NP (NN cell) (NNS lines) (CC and) (NNS tumors)))))) (, ,) (NP (NP (DT the) (NN translation)) (PP (IN into) (S (VP (VBG predicting) (NP (NN drug) (NN response)) (PP (IN in) (NP (NNS tumors))))))) (VP (VBZ remains) (ADJP (JJ challenging))) (. .))
(S (ADVP (RB Here)) (NP (PRP we)) (VP (VBD proposed) (NP (DT a) (NN DNN) (NN model)) (S (VP (TO to) (VP (VB predict) (NP (NN drug) (NN response)) (PP (VBN based) (PP (IN on) (NP (NP (NN mutation) (CC and) (NN expression) (NNS profiles)) (PP (IN of) (NP (NP (DT a) (NN cancer) (NN cell)) (CC or) (NP (DT a) (NN tumor))))))))))) (. .))
(S (NP (DT The) (NN model)) (VP (VBZ contains) (NP (NP (DT a) (NN mutation)) (CC and) (NP (NP (DT an) (NN expression) (NNS encoders)) (VP (VBN pre-trained) (S (VP (VBG using) (NP (DT a) (JJ large) (NN pan-cancer) (NN dataset)) (PP (IN to) (NP (NP (NP (JJ abstract) (NN core) (NNS representations)) (PP (IN of) (NP (NML (JJ high) (HYPH -) (NN dimension)) (NNS data)))) (, ,) (VP (VBN followed) (PP (IN by) (NP (DT a) (NN drug) (NN response) (NN predictor) (NN network)))))))))))) (. .))
(S (PP (VBN Given) (NP (NP (DT a) (NN pair)) (PP (IN of) (NP (NN mutation) (CC and) (NN expression) (NNS profiles))))) (, ,) (NP (DT the) (NN model)) (VP (VBZ predicts) (NP (NP (NN IC50) (NNS values)) (PP (IN of) (NP (CD 265) (NNS drugs))))) (. .))
(S (NP (PRP We)) (VP (VP (VBD trained) (CC and) (VBD tested) (NP (NP (DT the) (NN model)) (PP (IN on) (NP (NP (DT a) (NN dataset)) (PP (IN of) (NP (CD 622) (NML (NN cancer) (NN cell)) (NNS lines))))))) (CC and) (VP (VBD achieved) (NP (NP (DT an) (JJ overall) (NN prediction) (NN performance)) (PP (IN of) (NP (ADJP (JJ mean) (JJ squared)) (NN error)))) (PP (IN at) (NP (CD 1.96))) (PRN (-LRB- -LRB-) (NP (NML (NN log) (HYPH -) (NN scale)) (NN IC50) (NNS values)) (-RRB- -RRB-)))) (. .))
(S (NP (DT The) (NN performance)) (VP (VBD was) (ADJP (JJ superior) (PP (IN in) (NP (NN prediction) (NN error) (CC or) (NN stability)))) (PP (IN than) (NP (NP (CD two) (JJ classical) (NNS methods)) (CC and) (NP (NP (CD four) (NN analog) (NNS DNNs)) (PP (IN of) (NP (PRP$ our) (NN model))))))) (. .))
(S (NP (PRP We)) (ADVP (RB then)) (VP (VBD applied) (NP (DT the) (NN model)) (S (VP (TO to) (VP (VB predict) (NP (NP (NN drug) (NN response)) (PP (IN of) (NP (NP (CD 9,059) (NNS tumors)) (PP (IN of) (NP (CD 33) (NN cancer) (NNS types)))))))))) (. .))
(S (NP (DT The) (NN model)) (VP (VBD predicted) (NP (NP (NP (DT both)) (VP (VBN known) (, ,) (PP (VBG including) (NP (NP (NNP EGFR) (NNS inhibitors)) (PP (IN in) (NP (JJ non-small) (NML (NN cell) (NN lung)) (NN cancer))))))) (CC and) (NP (NP (NN tamoxifen)) (PP (IN in) (NP (NML (NN ER) (SYM +) (NN breast)) (NN cancer)))) (, ,) (CC and) (NP (JJ novel) (NN drug) (NNS targets)))) (. .))
(S (NP (DT The) (JJ comprehensive) (NN analysis)) (ADVP (RB further)) (VP (VBD revealed) (NP (DT the) (JJ molecular) (NNS mechanisms)) (S (VP (VBG underlying) (NP (DT the) (NN resistance)) (PP (IN to) (NP (NP (NP (DT a) (JJ chemotherapeutic) (NN drug) (NN docetaxel)) (PP (IN in) (NP (DT a) (NN pan-cancer) (NN setting)))) (CC and) (NP (NP (DT the) (JJ anti-cancer) (NN potential)) (PP (IN of) (NP (NP (DT a) (JJ novel) (NN agent)) (, ,) (NP (NN CX) (HYPH -) (CD 5461)) (, ,)))))) (PP (IN in) (S (VP (VBG treating) (NP (NP (NNS gliomas)) (CC and) (NP (JJ hematopoietic) (NNS malignancies))))))))) (. .))
(S (ADVP (RB Overall)) (, ,) (NP (PRP$ our) (NN model) (CC and) (NNS findings)) (VP (VBP improve) (NP (NP (NP (DT the) (NN prediction)) (PP (IN of) (NP (NN drug) (NN response)))) (CC and) (NP (NP (DT the) (NN identification)) (PP (IN of) (NP (JJ novel) (JJ therapeutic) (NNS options)))))) (. .))
